Longitude Capital Partners III, LLC's Net Worth
$280 Million
Who is Longitude Capital Partners III, LLC?
Longitude Capital Partners III, LLC has an estimated net worth of $280 Million. This is based on reported shares across multiple companies, which include Inozyme Pharma, Inc., Axonics Modulation Technologies, Inc., Talaris Therapeutics, Inc., Sierra Oncology, Inc., 89bio, Inc., and Molecular Templates, Inc..
SEC CIK
Longitude Capital Partners III, LLC's CIK is 0001713663
Past Insider Trading and Trends
2020 was Longitude Capital Partners III, LLC's most active year for acquiring shares with 11 total transactions. Longitude Capital Partners III, LLC's most active month to acquire stocks was the month of October. 2020 was Longitude Capital Partners III, LLC's most active year for disposing of shares, totalling 7 transactions. Longitude Capital Partners III, LLC's most active month to dispose stocks was the month of April. 2020 saw Longitude Capital Partners III, LLC paying a total of $12,999,975.00 for 4,418,724 shares, this is the most they've acquired in one year. In 2022 Longitude Capital Partners III, LLC cashed out on 3,616,896 shares for a total of $19,498,050.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Inozyme Pharma, Inc. (INZY) Snapshot price: $5.365
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +48.06% | 1.35M |
$3.69 | $4,999,950.00 | 4.17M |
Apr 19
| |||
Form 4
|
∞
| 2.82M |
$16.00 |
—
| 2.82M |
Jul 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Axonics Modulation Technologies, Inc. (AXNX) Snapshot price: $67.79
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.93M |
$15.00 |
—
| 2.93M |
Nov 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Talaris Therapeutics, Inc. (TRML) Snapshot price: $35.42
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.22M |
$17.00 |
—
| 3.22M |
May 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Sierra Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -98.59% | -2.12M |
—
|
—
| 30.38K |
Apr 27
| |||
Form 4
|
∞
| 175K |
$27.00 | $4,725,000.00 | 175K |
Feb 2
| |||
Form 4
| +33.00% | 487.45K |
$13.20 | $6,434,353.20 | 1.96M |
Jan 25
| |||
Form 4
|
∞
| 1.48M |
—
|
—
| 1.48M |
Jan 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
89bio, Inc. (ETNB) Snapshot price: $8.395
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -32.45% | -844.06K |
—
|
—
| 1.76M |
Nov 16
| |||
Form 4
| +4.38% | 109.09K |
$27.50 | $2,999,975.00 | 2.6M |
Jul 10
| |||
Form 4
|
∞
| 2.49M |
$16.00 |
—
| 2.49M |
Nov 11 - Nov 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |